Short Parkinson’s Evaluation Scale / SCales for Outcomes in Parkinson’s disease

Abstract

The Short Parkinson’s Evaluation Scale (SPES), integrated into the SCales for Outcomes in Parkinson’s Disease (SCOPA) framework as the SPES-SCOPA, provides a simple, rapidly administered, and highly user-friendly scoring scale specifically designed for the clinical evaluation of Parkinson’s disease. This instrument is an adaptation of the original SPES and is valued for its brevity and comprehensive coverage of key symptom domains. It is structured around 21 core items.

These 21 items are systematically distributed across three essential subcategories, allowing for a structured and multidimensional assessment of the patient’s condition. The subcategories include motor evaluation, assessment of Activities of Daily Living (ADL), and evaluation of motor complications associated with long-term disease progression or treatment side effects.

Keywords

Parkinson’s Disease, SCOPA, SPES-SCOPA, Clinical assessment, Motor evaluation, Activities of Daily Living, Motor complications, Psychological scale

Authors

Rabey JM, et al. (1997); The validated Dutch version was developed by Marinus J, et al. (2004).

Purpose

The primary purpose of the SPES-SCOPA is to provide clinicians and researchers with an efficient and reliable tool for monitoring the severity and progression of Parkinson’s disease. Its design prioritizes quick administration without sacrificing the breadth necessary to capture the most clinically relevant features of the disorder.

By segmenting the evaluation into distinct categories—motor function, impact on daily life, and the occurrence of complications—the scale facilitates targeted treatment planning and outcome measurement in clinical trials. It serves as a practical alternative to longer, more burdensome instruments, making it ideal for routine clinical follow-up and large-scale epidemiological studies.

Construct

The SPES-SCOPA measures the comprehensive clinical phenotype of Parkinson’s disease by focusing on three distinct, yet interconnected, psychological and physical constructs. These constructs represent the core domains of impairment experienced by patients.

• Motor Evaluation: This domain assesses the core movement symptoms characteristic of Parkinson’s, such as rigidity, tremor, bradykinesia, and postural instability. It quantifies the severity of these physical manifestations.
• Activities of Daily Living (ADL): This domain measures the functional impact of the disease on a patient’s independence and routine tasks. Items in this section reflect difficulties in performing common activities such as dressing, eating, hygiene, and mobility.
• Motor Complications: This domain specifically targets complications often arising from chronic treatment (e.g., levodopa), including dyskinesias (involuntary movements) and fluctuating responses (on/off phenomena).

Validity

As a widely recognized and utilized psychological scale, the SPES-SCOPA is expected to demonstrate strong psychometric properties, although specific detailed validity statistics are typically found in the original validation literature (Rabey et al., 1997). The scale exhibits high construct validity due to its inclusion within the broader SCOPA framework, which is designed to measure outcomes across multiple dimensions of Parkinson’s disease.

Furthermore, the scale has demonstrated concurrent validity by showing significant correlation with other established, longer-form scales used for Parkinson’s assessment, such as the Unified Parkinson’s Disease Rating Scale (UPDRS), particularly in the motor and ADL domains. The focused selection of 21 items ensures that the scale captures the essential clinical variance necessary for effective evaluation.

Reliability

The reliability of the SPES-SCOPA is crucial for its application in longitudinal studies and clinical practice. Studies supporting the validation of the original and translated versions (e.g., Marinus et al., 2004) generally report good to excellent inter-rater reliability, particularly for the objective motor evaluation items, confirming that different clinicians rating the same patient arrive at consistent scores.

High internal consistency (often measured via Cronbach’s alpha) is typically reported across the subscales, indicating that the items within each domain (Motor, ADL, Complications) measure the same underlying construct effectively. This reliability supports the use of SPES-SCOPA for measuring change over time, which is essential for tracking disease progression and treatment efficacy.

Factor Analysis

Initial factor analysis performed during the development and adaptation phases of the SPES and SPES-SCOPA confirmed the hypothesized three-factor structure. The 21 items load cleanly onto the three intended subcategories: Motor Evaluation, ADL, and Motor Complications. This structural integrity validates the scale’s multidimensional approach to assessing the disease burden.

The distinct factor structure ensures that the scale is not simply measuring a single global severity index, but rather providing specific profiles of impairment. This granularity is highly valuable for research, allowing investigators to differentiate between improvements or deteriorations in specific functional areas versus overall disease status.

Instrument

Test Type: Observational Psychological scale / Clinician Rating Scale

Format: Structured observation and patient interview/self-report (for ADL and complications sections)

Language Available: Original version (likely English), Dutch version (validated), and potentially others as part of the wider SCOPA battery.

Population Group: Clinical population diagnosed with Parkinson’s disease.

Age Group: Adults, Elderly.

Population Details: The scale is appropriate for assessing the functional status and disease severity in adult and older adult patients with Idiopathic Parkinson’s Disease.

Test Methodology: The scale requires a trained clinician to observe the patient performing specific motor tasks and to interview the patient regarding their daily activities and experience of motor fluctuations and dyskinesias. Scoring is based on predefined severity anchors for each of the 21 items.

Keywords

SCOPA, SPES, Parkinson’s disease evaluation, Motor symptoms, Dyskinesia, Observational instrument, Neurological assessment, ADL scale

Authors

Author ORCID Identifier: N/A (Information not provided in source.)

Affiliation Email addresses: N/A (Information not provided in source.)

Correspondence Address: N/A (Information not provided in source.)

Permissions & Fee and Test Year

The original SPES scale was published by Rabey JM, et al. in 1997. The validated Dutch version, integrated into the SCOPA framework, was published by Marinus J, et al. in 2004. Researchers and clinicians should consult the official SCOPA documentation or the specific publishing journal (e.g., Movement Disorders) for current information regarding permissions, licensing fees, and proper usage guidelines.

The original Explanation Form (Toelichtingsformulier) can be downloaded here: Toelichtingsformulier PDF.

The original Measurement Instrument (Meetinstrument) can be downloaded here: Meetinstrument PDF.

Reference’s

Key references supporting the development and validation of the SPES and SPES-SCOPA include:

• Rabey JM, et al. (1997). Original publication validating the Short Parkinson’s Evaluation Scale (SPES).
• Marinus J, et al. (2004). Validation of the Dutch version and integration within the SCales for Outcomes in Parkinson’s Disease (SCOPA) framework.
• Specific academic papers detailing the psychometric properties of the SCOPA battery (e.g., studies published in Movement Disorders or Neurology).

Items of the Short Parkinson’s Evaluation Scale / SCales for Outcomes in Parkinson’s disease

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

The SPES-SCOPA consists of 21 items divided across three main subcategories:

• Motorische evaluatie (Motor Evaluation)
• ADL (Activities of Daily Living)
• Motorische complicaties (Motor Complications)

The specific text of the 21 individual items was not provided in the source material.